Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 11/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.57 |
| ▸ | CDC37 | Q16543 | 1/20 | 0.52 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1669843 | 0.95 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL1672118 | 0.92 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL11908245 | 0.92 | HSP90AA1 (0.69) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL15980482 | 0.88 | HSP90AB1 (0.60) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL15980508 | 0.87 | HSP90AB1 (0.59) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL1671854 | 0.87 | HSP90AB1 (0.68) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL11908735 | 0.87 | HSP90AB1 (0.57) | HSP90AA1HSP90AB1ERBB2TRAP1 | |
| SCHEMBL18203470 | 0.86 | HSP90AB1 (0.57) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL1669898 | 0.86 | HSP90AB1 (0.57) | HSP90AA1HSP90AB1ERBB2CDC37TRAP1 | |
| SCHEMBL17771000 | 0.86 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1ERBB2TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3091019-A2 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | Sloan Kettering Institute For Cancer Research (US) | 2016-11-09 | — | — | EP | claimed |
| US-20210161902-A1 | EPICHAPEROME INHIBITOR THERAPY FOR TRAUMATIC BRAIN INJURY AND SEQUELAE THEREOF | SAMUS THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| CN-111683658-A | Multi-protein complex inhibitor therapy for traumatic brain injury and sequelae thereof | 萨缪斯治疗股份有限公司 | 2020-09-18 | — | — | CN | disclosed |
| EP-3641751-A2 | EPICHAPEROME INHIBITOR THERAPY FOR TRAUMATIC BRAIN INJURY AND SEQUELAE THEREOF | Samus Therapeutics, Inc. (US) | 2020-04-29 | — | — | EP | disclosed |
| US-20200069592-A1 | HSP90 INHIBITOR ORAL FORMULATIONS AND RELATED METHODS | SAMUS THERAPEUTICS, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| EP-3615008-A1 | HSP90 INHIBITOR ORAL FORMULATIONS AND RELATED METHODS | Samus Therapeutics, Inc. (US) | 2020-03-04 | — | — | EP | disclosed |
| EP-3091019-B1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2019-04-03 | — | — | EP | disclosed |
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2019-01-08 | — | — | US | disclosed |
| WO-2018237211-A2 | EPICHAPEROME INHIBITOR THERAPY FOR TRAUMATIC BRAIN INJURY AND SEQUELAE THEREOF | SAMUS THERAPEUTICS, INC. (US) | 2018-12-27 | — | — | WO | disclosed |
| WO-2018200534-A1 | HSP90 INHIBITOR ORAL FORMULATIONS AND RELATED METHODS | SAMUS THERAPEUTICS, INC. (US) | 2018-11-01 | — | — | WO | disclosed |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-10-27 | — | — | US | disclosed |
| US-9328114-B2 | Hsp90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2016-05-03 | — | — | US | disclosed |
| US-20120208806-A1 | Hsp90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172863-B2 | Purine derivatives useful as HSP90 inhibitors | XDH, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 4/4885ERBB2 4122/4885 |
| US-20120208806-A1 | Hsp90 Inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885ERBB2 2315/4885 |
| US-20210161902-A1 | EPICHAPEROME INHIBITOR THERAPY FOR TRAUMATIC BRAIN INJURY AND SEQUELAE THEREOF | HSP90B1, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885ERBB2 2451/4885 |
| US-20200069592-A1 | HSP90 INHIBITOR ORAL FORMULATIONS AND RELATED METHODS | HSP90AB1, HSP90B1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 1/4885ERBB2 2545/4885 |
| US-20160310497-A1 | PURINE DERIVATIVES USEFUL AS HSP90 INHIBITORS | XDH, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 4/4885ERBB2 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.